EcoDrugPlus

Il2 Inducible T Cell Kinase

Ensembl ID : ENSBMUG00000015489
Gene Symbol: ITK
2 Cross references
201 Possible Orthologues:

Janus Kinase 1

Ensembl ID : ENSBMUG00000002390
Gene Symbol: JAK1
3 Cross references
238 Possible Orthologues:

Janus Kinase 2

Ensembl ID : ENSBMUG00000005141
Gene Symbol: JAK2
3 Cross references
265 Possible Orthologues:

Janus Kinase 3

Ensembl ID : ENSBMUG00000025470
Gene Symbol: JAK3
3 Cross references
103 Possible Orthologues:

Kit Proto-Oncogene, Receptor Tyrosine Kinase

Ensembl ID : ENSBMUG00000020553
Gene Symbol: KIT
3 Cross references
211 Possible Orthologues:

Kras Proto-Oncogene, Gtpase

Ensembl ID : ENSBMUG00000019982
Gene Symbol: KRAS
3 Cross references
203 Possible Orthologues:

Lck Proto-Oncogene, Src Family Tyrosine Kinase

Ensembl ID : ENSBMUG00000008853
Gene Symbol: LCK
3 Cross references
120 Possible Orthologues:

Lyn Proto-Oncogene, Src Family Tyrosine Kinase

Ensembl ID : ENSBMUG00000011591
Gene Symbol: LYN
3 Cross references
197 Possible Orthologues:

Malt1 Paracaspase

Ensembl ID : ENSBMUG00000002149
Gene Symbol: MALT1
3 Cross references
197 Possible Orthologues:

Mapk Activated Protein Kinase 2

Ensembl ID : ENSBMUG00000025352
Gene Symbol: MAPKAPK2
3 Cross references
240 Possible Orthologues:

Mapk Activated Protein Kinase 5

Ensembl ID : ENSBMUG00000025368
Gene Symbol: MAPKAPK5
3 Cross references
179 Possible Orthologues:

Mapk Interacting Serine/threonine Kinase 1

Ensembl ID : ENSBMUG00000019092
Gene Symbol: MKNK1
3 Cross references
168 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).